Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
RedChip Companies将于本周六美国东部时间晚上7点在Bloomberg电视台上播出采访Enlivex Therapeutics Ltd.（纳斯达克：ENLV）和Biotricity，Inc.（纳斯达克：BTCY）的节目RedChip Small Stocks, Big Money show。Bloomberg电视台在美国约7300万户家庭中可接收。
Access the interviews in their entirety at:
Soligenix:
Enlivex Therapeutics:
Biotricity:
Enlivex Therapeutics:
Biotricity:
Oren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money show on Bloomberg TV to provide a corporate update. Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Diseases such as osteoarthritis, sepsis, and many others reprogram macrophages out of their homeostatic state. These nonhomeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action and resolution for conditions which are life threatening and debilitating "unmet medical needs".
Enlivex Therapeutics的CEO Oren Hershkovitz博士将在Bloomberg电视台的RedChip Small Stocks, Big Money show中提供公司动态更新。Enlivex是一家临床阶段的巨噬细胞重编程免疫治疗公司，正在开发AllocetraTm，这是一种通用的现成细胞治疗方案，旨在重新编程主要免疫细胞巨噬细胞回到它们的稳态状态。疾病如骨关节炎、败血症和许多其他疾病会使巨噬细胞失去稳态，而这些非稳态巨噬细胞会严重加剧相关疾病的严重程度。通过恢复巨噬细胞的稳态，Allocetra具有提供一种新型的免疫治疗机制和解决方案的潜力，适用于威胁生命和造成严重影响的“未满足医疗需求”条件。
In an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of cardiac monitoring solutions, which includes the FDA-cleared Bioflux and Biocore devices, targeting a total addressable market of $35 billion. With its solutions utilized daily by cardiologists across 34 states and 500 centers, Biotricity has captured an 8% market share in cardiology, bolstered by high retention rates of approximately 99% and a recurring revenue base that boasts strong LTV-to-CAC ratios. Biotricity is on a clear path to profitability and expects to be EBITDA positive before the end of 2024.
在一次独家采访中，Biotricity的创始人兼首席执行官Dr. Waqaas Al-Siddiq将分享该公司创新心脏监测解决方案的见解，其中包括FDA认证的Bioflux和Biocore设备，瞄准总可寻址市场达35亿美元。随着其解决方案每天被34个州和500个中心的心脏病专家使用，Biotricity已经在心脏病学领域占据了8%的市场份额，高维持率约为99%和强有力的LTV-to-CAC比率的不断增长的再生收入基础也为此提供了支撑。Biotricity正在走向盈利，预计在2024年底之前实现EBITDA盈利。
About Enlivex Therapeutics Ltd.
关于Enlivex Therapeutics Ltd.
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit .
Enlivex是一家临床阶段的巨噬细胞重编程免疫治疗公司，正在开发Allocetra，这是一种通用的现成细胞治疗方案，旨在重新编程巨噬细胞回到其稳态状态。重置非稳态巨噬细胞的稳态状态对于免疫系统的重新平衡和解决威胁生命的疾病非常重要。更多信息，访问 。
About Biotricity
关于Biotricity
Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit and follow us on Twitter and LinkedIn.
Biotricity正在通过实现遥测与慢性病管理之间的进一步连接，集中于心脏学领域，以此来改变保健市场。医生和病人都信任Biotricity的预防性护理和个人护理的卓越标准，包括针对慢性疾病的诊断和后诊断解决方案。该公司开发了全面的面向医疗和消费市场的远程健康监测解决方案。详情请访问，同样您也可以关注我们的 Twitter 和 LinkedIn。
About RedChip Companies
关于RedChip公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip公司是一家国际投资关系、媒体和研究公司，专注于微型股和小型股公司。30多年来，RedChip为客户提供了具体的、可量化的结果。我们的每周在线报告《Small Stocks，Big Money》每周在线投资者共计60,000人。RedChip已经发展成为行业中最全面的服务平台，为微型库存和小型库存提供以下服务：为其股票调查提供遍布全球的分销网络；在美国主要城市进行零售和机构路演；对股票经纪人、RIA、机构和家族办公室进行出口推广；数字媒体投资者关系平台，已经产生了数百万独特的投资者浏览量；为投资者举办网络研讨会和小组电话；电视节目《Small Stocks, Big Money》每周在Bloomberg US播出，本地和全国市场的电视广告；公司和产品视频；网站设计；和传统的投资者关系服务，包括新闻稿撰写、投资者演示文稿开发、季度电话会议剧本撰写、战略咨询、筹资等。
To learn more about RedChip's products and services, please visit:
要了解更多有关RedChip的产品和服务的信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“发现明日的蓝筹股”
Follow RedChip on LinkedIn:
在LinkedIn上关注RedChip：
Follow RedChip on Facebook:
在Facebook上关注RedChip：
Follow RedChip on Instagram:
在Instagram上关注RedChip：
Follow RedChip on Twitter:
在Twitter上关注RedChip：
Follow RedChip on YouTube:
在YouTube上关注RedChip：
Follow RedChip on Rumble:
在Rumble上关注RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系方式：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
--END--
SOURCE: RedChip
来源：RedChip